{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:09:15Z","timestamp":1790399355703,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2505100"],"award-info":[{"award-number":["2022YFC2505100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005198","name":"Chinese Foundation for Hepatitis Prevention and Control","doi-asserted-by":"publisher","award":["2021ZC032"],"award-info":[{"award-number":["2021ZC032"]}],"id":[{"id":"10.13039\/501100005198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.lanwpc.2023.100738","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T07:10:39Z","timestamp":1678345839000},"page":"100738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation"],"prefix":"10.1016","volume":"35","author":[{"given":"Sihui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Bin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8880-0392","authenticated-orcid":false,"given":"Yihua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingfeng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghua","family":"huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanwpc.2023.100738_bib1","series-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact","year":"2021"},{"key":"10.1016\/j.lanwpc.2023.100738_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.lanwpc.2023.100738_bib3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3201\/eid2305.161477","article-title":"Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China","volume":"23","author":"Cui","year":"2017","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.lanwpc.2023.100738_bib4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S2468-1253(21)00267-3","article-title":"New WHO guidance for country validation of viral hepatitis B and C elimination","volume":"6","author":"Easterbrook","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"25","key":"10.1016\/j.lanwpc.2023.100738_bib5","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.3748\/wjg.v21.i25.7869","article-title":"Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis","volume":"21","author":"Xu","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"9865","key":"10.1016\/j.lanwpc.2023.100738_bib6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lanwpc.2023.100738_bib7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.lanwpc.2023.100738_bib8","series-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitisB infection","year":"2015"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100738_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.lanwpc.2023.100738_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"12","key":"10.1016\/j.lanwpc.2023.100738_bib11","first-page":"938","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"5","key":"10.1016\/j.lanwpc.2023.100738_bib12","first-page":"769","article-title":"Guidelines for prevention and treatment of chronic hepatitis B","volume":"9","author":"Wang","year":"2021","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"9","key":"10.1016\/j.lanwpc.2023.100738_bib13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/MCG.0000000000000544","article-title":"Histologic disease in Chinese chronic hepatitis B patients with low viral loads and persistently normal alanine aminotransferase levels","volume":"50","author":"Wang","year":"2016","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.lanwpc.2023.100738_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2893.2010.01270.x","article-title":"Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase","volume":"17","author":"Gui","year":"2010","journal-title":"J\u00a0Viral Hepat"},{"issue":"10","key":"10.1016\/j.lanwpc.2023.100738_bib15","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/liv.13705","article-title":"Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B: a large national cohort study","volume":"38","author":"Shim","year":"2018","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.lanwpc.2023.100738_bib16","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/apt.16097","article-title":"East Asia expert opinion on treatment initiation for chronic hepatitis B","volume":"52","author":"Kao","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.lanwpc.2023.100738_bib17","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","article-title":"The clinical significance of persistently normal ALT in chronic hepatitis B infection","volume":"47","author":"Lai","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.lanwpc.2023.100738_bib18","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.lanwpc.2023.100738_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.lanwpc.2023.100738_bib20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100738_bib21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/hep.29874","article-title":"Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance","volume":"68","author":"Fung","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.lanwpc.2023.100738_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-002306","article-title":"Combating hepatitis B and C by 2030: achievements, gaps, and options for actions in China","volume":"5","author":"Chen","year":"2020","journal-title":"BMJ Glob Health"},{"issue":"Suppl 1","key":"10.1016\/j.lanwpc.2023.100738_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2893.2010.01274.x","article-title":"Management of chronic hepatitis B: experience from China","volume":"17","author":"Sun","year":"2010","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100738_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17512433.2019.1567327","article-title":"Novel developments of hepatitis B: treatment goals, agents and monitoring tools","volume":"12","author":"Mak","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10161","key":"10.1016\/j.lanwpc.2023.100738_bib25","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lanwpc.2023.100738_bib26","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jvh.13126","article-title":"Roadmap to functional cure of chronic hepatitis B: an expert consensus","volume":"26","author":"Ning","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100738_bib27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12072-022-10310-1","article-title":"Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU\/mL","volume":"16","author":"Lee","year":"2022","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100738_bib28","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000299","article-title":"Cost-effectiveness analysis of antiviral therapy for untreated minimally active chronic hepatitis B to prevent liver disease progression","volume":"12","author":"Lee","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"issue":"12","key":"10.1016\/j.lanwpc.2023.100738_bib29","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jval.2020.06.015","article-title":"Cost-effectiveness of testing and treatment for hepatitis B virus and hepatitis C virus infections: an analysis by scenarios, regions, and income","volume":"23","author":"Tordrup","year":"2020","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.lanwpc.2023.100738_bib30","doi-asserted-by":"crossref","first-page":"e1335","DOI":"10.1016\/S2214-109X(20)30277-1","article-title":"Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis","volume":"8","author":"Zou","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100738_bib31","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/S2214-109X(21)00517-9","article-title":"Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation","volume":"10","author":"Su","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"5","key":"10.1016\/j.lanwpc.2023.100738_bib32","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2352-3018(15)00020-X","article-title":"Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study","volume":"2","author":"Zhang","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.lanwpc.2023.100738_bib47","first-page":"100726","article-title":"Cost-effectiveness of artificial intelligence-assisted liquid-based cytology testing for cervical cancer screening in China","author":"Shen","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.lanwpc.2023.100738_bib48","first-page":"100700","article-title":"Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030","volume":"33","author":"Liu","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.lanwpc.2023.100738_bib49","article-title":"Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: Reinterpreting the primary care and specialty divide","author":"Zhang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"3","key":"10.1016\/j.lanwpc.2023.100738_bib33","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1093\/cid\/ciac385","article-title":"Simplifying treatment criteria in chronic hepatitis B: reducing barriers to elimination","volume":"76","author":"Wong","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100738_bib34","first-page":"131","article-title":"Expert opinions on expanding the antiviral treatment of chronic hepatitis B","volume":"20","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"20","key":"10.1016\/j.lanwpc.2023.100738_bib35","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.3748\/wjg.v20.i20.6262","article-title":"Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments","volume":"20","author":"Tang","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.lanwpc.2023.100738_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3851\/IMP3372","article-title":"Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside\/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study","volume":"25","author":"Jia","year":"2020","journal-title":"Antivir Ther"},{"issue":"9","key":"10.1016\/j.lanwpc.2023.100738_bib37","doi-asserted-by":"crossref","first-page":"e3317","DOI":"10.1093\/cid\/ciaa898","article-title":"Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus","volume":"73","author":"Huang","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.lanwpc.2023.100738_bib38","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/14760584.2021.1927723","article-title":"Reduced mother-to-child transmission of hepatitis B after implementation of completely charge-free active-passive immunoprophylaxis: an observational cohort study","volume":"20","author":"Xu","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"10.1016\/j.lanwpc.2023.100738_bib39","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1080\/21645515.2021.1992213","article-title":"The optimal interval for post-vaccination serological test in infants born to mothers with positive hepatitis B surface antigen","volume":"17","author":"Huang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100738_bib40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.lanwpc.2023.100738_bib41","article-title":"Per capita GDP exceeds the world average China\u2019s future development depends on three factors","year":"2022","journal-title":"Chin J Clin Nutr"},{"issue":"6","key":"10.1016\/j.lanwpc.2023.100738_bib42","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/jmv.22048","article-title":"High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe","volume":"83","author":"Gobel","year":"2011","journal-title":"J\u00a0Med Virol"},{"issue":"11","key":"10.1016\/j.lanwpc.2023.100738_bib43","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/gut.2005.065136","article-title":"Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications","volume":"54","author":"Yuen","year":"2005","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100738_bib44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3350\/cmh.2021.0314","article-title":"Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis","volume":"28","author":"Jeong","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.lanwpc.2023.100738_bib45","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3350\/cmh.2022.0012","article-title":"RNA interference as a novel treatment strategy for chronic hepatitis B infection","volume":"28","author":"Hui","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.lanwpc.2023.100738_bib46","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3350\/cmh.2022.0037","article-title":"Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease","volume":"28","author":"Sohn","year":"2022","journal-title":"Clin Mol Hepatol"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606523000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606523000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:39:56Z","timestamp":1763001596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606523000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":49,"alternative-id":["S2666606523000561"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100738","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100738"}}